Role of LRRK2 kinase dysfunction in Parkinson disease

Azad Kumar; Mark R. Cookson

doi:10.1017/S146239941100192X

Role of LRRK2 kinase dysfunction in Parkinson disease

Published online by Cambridge University Press: 13 June 2011

Azad Kumar and

Mark R. Cookson

Show author details

Azad Kumar: Affiliation:
Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Mark R. Cookson*: Affiliation:
Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
*: *Corresponding author: Mark R. Cookson, Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Bethesda, MD 20892-3707, USA. E-mail: cookson@mail.nih.gov

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Parkinson disease is a common and usually sporadic neurodegenerative disorder. However, a subset of cases are inherited and, of these, mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most frequent genetic cause of disease. Here, we will discuss recent progress in understanding how LRRK2 mutations lead to disease and how this might have therapeutic implications. The effect of mutations on LRRK2 enzyme function provides clues as to which functions of the protein are important to disease. Recent work has focused on the kinase and GTP-binding domains of LRRK2, and it is assumed that these will be therapeutically important, although there is a substantial amount of work to be done to address this hypothesis.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 13 , March 2011 , e20

DOI: https://doi.org/10.1017/S146239941100192X [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2011. This is a work of the US Government and is not subject to copyright protection in the USA

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Cookson, M.R. (2005) The biochemistry of Parkinson's disease. Annual Reviews of Biochemistry 74, 29-52CrossRef Google Scholar PubMed

2Cookson, M.R. and Bandmann, O. (2010) Parkinson's disease: insights from pathways. Human Molecular Genetics 19, R21-R27CrossRef Google Scholar PubMed

3Hardy, J. (2010) Genetic analysis of pathways to Parkinson disease. Neuron 68, 201-206CrossRef Google Scholar PubMed

4Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Reviews. Neuroscience 11, 791-797CrossRef Google Scholar PubMed

5Taymans, J.M. and Cookson, M.R. (2010) Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 32, 227-235CrossRef Google Scholar PubMed

6Manning, G. et al. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934CrossRef Google Scholar PubMed

7Marin, I., van Egmond, W.N. and van Haastert, P.J. (2008) The Roco protein family: a functional perspective. FASEB Journal 22, 3103-3110CrossRef Google Scholar

8Gotthardt, K. et al. (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO Journal 27, 2239-2249CrossRef Google Scholar PubMed

9Berger, Z., Smith, K.A. and Lavoie, M.J. (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49, 5511-5523CrossRef Google Scholar PubMed

10Dzamko, N. et al. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14–3–3 binding and altered cytoplasmic localization. Biochemical Journal 430, 405-413CrossRef Google Scholar

11Giasson, B.I. et al. (2006) Biochemical and pathological characterization of Lrrk2. Annals of Neurology 59, 315-322CrossRef Google Scholar PubMed

12Greggio, E. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of Disease 23, 329-341CrossRef Google Scholar PubMed

13Nichols, R.J. et al. (2010) 14–3–3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochemical Journal 430, 393-404CrossRef Google Scholar PubMed

14West, A.B. et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America 102, 16842-16847CrossRef Google Scholar PubMed

15Deng, J. et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proceedings of the National Academy of Sciences of the United States of America 105, 1499-1504CrossRef Google Scholar PubMed

16Guo, L. et al. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Experimental Cell Research 313, 3658-3670CrossRef Google Scholar PubMed

17Lewis, P.A. et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochemical and Biophysical Research Communications 357, 668-671CrossRef Google Scholar PubMed

18Li, X. et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Journal of Neurochemistry 103, 238-247CrossRef Google Scholar PubMed

19Ito, G. et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388CrossRef Google Scholar

20Liu, M. et al. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 49, 2008-2017CrossRef Google Scholar PubMed

21Gloeckner, C.J. et al. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. Journal of Proteome Research 9, 1738-1745CrossRef Google Scholar PubMed

22Greggio, E. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochemical and Biophysical Research Communications 389, 449-454CrossRef Google Scholar PubMed

23Kamikawaji, S., Ito, G. and Iwatsubo, T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963-10975CrossRef Google Scholar PubMed

24Pungaliya, P.P. et al. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One 5, e13672CrossRef Google Scholar PubMed

25Greggio, E. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. Journal of Biological Chemistry 283, 16906-16914CrossRef Google Scholar PubMed

26Jorgensen, N.D. et al. (2009) The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4, e8463CrossRef Google Scholar PubMed

27Klein, C.L. et al. (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. Journal of Neurochemistry 111, 703-715CrossRef Google Scholar PubMed

28Ko, H.S. et al. (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proceedings of the National Academy of Sciences of the United States of America 106, 2897-2902CrossRef Google Scholar PubMed

29Lu, B. et al. (2010) Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. Biochimica et Biophysica Acta 1804, 1780-1784CrossRef Google Scholar PubMed

30Sen, S., Webber, P.J. and West, A.B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. Journal of Biological Chemistry 284, 36346-36356CrossRef Google Scholar PubMed

31Alegre-Abarrategui, J. et al. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Human Molecular Genetics 18, 4022-4034CrossRef Google Scholar

32Hatano, T. et al. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Human Molecular Genetics 16, 678-690CrossRef Google Scholar PubMed

33Miklossy, J. et al. (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. Journal of Neuropathology and Experimental Neurology 65, 953-963CrossRef Google Scholar PubMed

34Biskup, S. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology 60, 557-569CrossRef Google Scholar PubMed

35Higashi, S. et al. (2009) Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. Journal of Neuropathology and Experimental Neurology 68, 994-1005CrossRef Google Scholar

36Funayama, M. et al. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Annals of Neurology 51, 296-301CrossRef Google Scholar PubMed

37Paisan-Ruiz, C. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600CrossRef Google Scholar PubMed

38Zimprich, A. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607CrossRef Google Scholar PubMed

39Funayama, M. et al. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Annals of Neurology 57, 918-921CrossRef Google Scholar PubMed

40Gilks, W.P. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415-416Google Scholar PubMed

41Goldwurm, S. et al. (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. Journal of Medical Genetics 42, e65CrossRef Google Scholar PubMed

42Infante, J. et al. (2006) LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neuroscience Letters 395, 224-226CrossRef Google Scholar PubMed

43Kachergus, J. et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. American Journal of Human Genetics 76, 672-680CrossRef Google Scholar PubMed

44Lesage, S. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. New England Journal of Medicine 354, 422-423CrossRef Google Scholar PubMed

45Lesage, S. et al. (2005) G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Annals of Neurology 58, 784-787CrossRef Google Scholar PubMed

46Lesage, S. et al. (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. American Journal of Human Genetics 77, 330-332CrossRef Google Scholar PubMed

47Ozelius, L.J. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine 354, 424-425CrossRef Google Scholar PubMed

48Rajput, A. et al. (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506-1508CrossRef Google Scholar PubMed

49Kumari, U. and Tan, E.K. (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS Journal 276, 6455-6463CrossRef Google Scholar PubMed

50Greggio, E. and Cookson, M.R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1, e0002CrossRef Google Scholar PubMed

51Daniels, V. et al. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. Journal of Neurochemistry 116, 304-315CrossRef Google Scholar PubMed

52West, A.B. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics 16, 223-232CrossRef Google Scholar PubMed

53Haugarvoll, K. and Wszolek, Z.K. (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism and Related Disorders 15 (Suppl 3), S205-S208CrossRef Google Scholar PubMed

54Alcalay, R.N. et al. (2010) Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Archives of Neurology 67, 1116-1122CrossRef Google Scholar

55Goldstein, D.S. et al. (2007) Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology 69, 1580-1584CrossRef Google Scholar PubMed

56Wider, C., Dickson, D.W. and Wszolek, Z.K. (2010) Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegenerative Diseases 7, 175-179CrossRef Google Scholar PubMed

57Cookson, M.R., Hardy, J. and Lewis, P.A. (2008) Genetic neuropathology of Parkinson's disease. International Journal Clinical Experimental Pathology 1, 217-231Google Scholar PubMed

58Kay, D.M. et al. (2005) Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Movement Disorders 20, 1077-1078CrossRef Google Scholar PubMed

59Dachsel, J.C. and Farrer, M.J. (2010) LRRK2 and Parkinson disease. Archives of Neurology 67, 542-547CrossRef Google Scholar PubMed

60Clark, L.N. et al. (2006) Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67, 1786-1791CrossRef Google Scholar PubMed

61Ruiz-Martinez, J. et al. (2010) Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Movement Disorders 25, 2340-2345CrossRef Google Scholar

62Gehrke, S. et al. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641CrossRef Google Scholar PubMed

63Imai, Y. et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO Journal 27, 2432-2443CrossRef Google Scholar PubMed

64Kanao, T. et al. (2010) Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Human Molecular Genetics 19, 3747-3758CrossRef Google Scholar PubMed

65Lee, S. et al. (2010) LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. Journal of Neuroscience 30, 16959-16969CrossRef Google Scholar PubMed

66Lee, S.B. et al. (2007) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochemical and Biophysical Research Communications 358, 534-539CrossRef Google Scholar PubMed

67Lin, C.H. et al. (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. Journal of Neuroscience 30, 13138-13149CrossRef Google Scholar PubMed

68Liu, Z. et al. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 105, 2693-2698CrossRef Google Scholar PubMed

69Ng, C.H. et al. (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. Journal of Neuroscience 29, 11257-11262CrossRef Google Scholar PubMed

70Tain, L.S. et al. (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nature Neuroscience 12, 1129-1135CrossRef Google Scholar PubMed

71Venderova, K. et al. (2009) Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Human Molecular Genetics 18, 4390-4404CrossRef Google Scholar

72Hsu, C.H. et al. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. Journal of Neurochemistry 112, 1593-1604CrossRef Google Scholar PubMed

73Saha, S. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. Journal of Neuroscience 29, 9210-9218CrossRef Google Scholar PubMed

74Sakaguchi-Nakashima, A. et al. (2007) LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Current Biology 17, 592-598CrossRef Google Scholar

75Samann, J. et al. (2009) Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. Journal of Biological Chemistry 284, 16482-16491CrossRef Google Scholar PubMed

76Yao, C. et al. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiology of Disease 40, 73-81CrossRef Google Scholar

77Wang, D. et al. (2008) Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Molecular Neurodegeneration 3, 3CrossRef Google Scholar PubMed

78Marin, I. (2008) Ancient origin of the Parkinson disease gene LRRK2. Journal of Molecular Evolution 67, 41-50CrossRef Google Scholar PubMed

79Andres-Mateos, E. et al. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Journal of Neuroscience 29, 15846-15850CrossRef Google Scholar PubMed

80Lin, X. et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64, 807-827CrossRef Google Scholar PubMed

81Tong, Y. et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America 107, 9879-9884CrossRef Google Scholar PubMed

82Tong, Y. et al. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proceedings of the National Academy of Sciences of the United States of America 106, 14622-14627CrossRef Google Scholar PubMed

83Li, X. et al. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. Journal of Neuroscience 30, 1788-1797CrossRef Google Scholar PubMed

84Li, Y. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neuroscience 12, 826-828CrossRef Google Scholar PubMed

85Melrose, H.L. et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiology of Disease 40, 503-517CrossRef Google Scholar PubMed

86Winner, B. et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiology of Disease 41, 706-716CrossRef Google Scholar PubMed

87Lee, B.D. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine 16, 998-1000CrossRef Google Scholar PubMed

88Dusonchet, J. et al. (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. Journal of Neuroscience 31, 907-912CrossRef Google Scholar PubMed

89Dachsel, J.C. et al. (2010) A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism and Related Disorders 16, 650-655CrossRef Google Scholar PubMed

90MacLeod, D. et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593CrossRef Google Scholar PubMed

91Parisiadou, L. et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. Journal of Neuroscience 29, 13971-13980CrossRef Google Scholar PubMed

92Nuytemans, K. et al. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Human Mutation 31, 763-780CrossRef Google Scholar

93Satake, W. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics 41, 1303-1307CrossRef Google Scholar PubMed

94Simon-Sanchez, J. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics 41, 1308-1312CrossRef Google Scholar PubMed

95Smith, W.W. et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience 9, 1231-1233CrossRef Google Scholar PubMed

96Liu, M. et al. (2010) Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2 – discovery of LRRK2 inhibitors. Analytical Biochemistry 404, 186-192CrossRef Google Scholar PubMed

97Nichols, R.J. et al. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochemical Journal 424, 47-60CrossRef Google Scholar PubMed

98Reichling, L.J. and Riddle, S.M. (2009) Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochemical and Biophysical Research Communications 384, 255-258CrossRef Google Scholar PubMed

99Deng, X. et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology 7, 203–25CrossRef Google Scholar PubMed

Article contents

Role of LRRK2 kinase dysfunction in Parkinson disease

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Role of LRRK2 kinase dysfunction in Parkinson disease

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests